Secondary analysis of the COVAIL booster trial (985 participants): the link between neutralising antibody titre and lower COVID-19 risk did not significantly vary with how closely the infecting virus matched the vaccine (all p>0.10); sequences from 129 of 195 cases.
Secondary analysisn = 985
Heng et al. The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances